TL;DR
In-vivo studies showed a reduction in tumor volume, increased accumulation of the drug in the brain, and enhanced antioxidant enzyme levels, with favorable pharmacokinetics, indicating that the nanoparticles are a promising system for the management of glioblastoma.
Glioblastoma is an aggressive form of brain cancer with limited treatment therapies due to the Blood-Brain Barrier (BBB), which makes it challenging for most medications to cross it and the difficulty of achieving tumour-specific targeting. Transferrin receptors (TfR) are overexpressed on endothelial cells of the b...
The outcomes of this research demonstrate the potential of PEGylated OLP-LNCs as an efficient nanocarrier for breast cancer treatment and improve its pharmacokinetic behavior after intravenous administration.
Background: Herein, we report on the development of a novel submicron-sized formulation that utilizes the somatostatin receptor agonist, octreotide (OCT), for the solubilization and targeted delivery of paclitaxel (PTX) and docetaxel (DTX) to the cancer cells. The formulation was prepared using a fast, single-step, and...
HNP–PTX is a promising candidate for further in vivo evaluation as an intranasal formulation for glioblastoma treatment and Cytotoxicity assays showed that HNP–PTX reduced cell viability more than both taxol and temozolomide (TMZ).
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
